natgillin/translations-raw huggingface dataset:
The method of claim 12, wherein the one or more doses of fentanyl, or a pharmaceutically acceptable salt thereof, is administered to the subject within at least 1 minute, 2 minutes, 5 minutes or 10 minutes prior to the administration of the initial fixed dose of the besylate salt of the compound of formula (I) to the subject. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno bilo kojem od prethodnih zahtjeva, naznačen time što se fentanil daje prije davanja CNS 7056, a prvenstveno u roku od 10 minuta, još poželjnije u roku od 5 minuta, i najpoželjnije u roku od 1 ili 2 minuta prije davanja CNS 7056.
The method of claim 15, wherein said disease is asthma or chronic obstructive pulmonary disease (COPD). 
Formulacija suhog praška za upotrebu prema patentnom zahtjevu 14, naznačeno time da bolest jest astma ili kronična opstruktivna plućna bolest (COPD).
An embodiment of the present invention relates to a compound of the following formula XIII, or a salt thereof, or a hydrate of the compound or the salt: 
Spoj prema slijedećoj formuli XIII, ili njegova sol, ili hidrat spoja ili njegova sol:
Freezing time to -48°C: 
Vrijeme zamrzavanja do -
A process of providing a molten material comprising introducing solid batch material into a melter, and melting the solid batch material in the melter by submerged combustion to afford a melt, and subjecting the melt to a flow pattern which when simulated by means of Computational Fluid Dynamics analysis shows a substantially toroidal melt flow pattern generated in the melt in the melter, comprising major centrally inwardly convergent flow vectors at the melt surface followed by downward oriented flow in proximity of the central axis of revolution of the toroidal melt flow pattern, with the central axis of revolution of the toroidal melt flow pattern being substantially vertical. 
Postupak dobivanja rastaljenog materijala koji se sastoji u unosu šarže čvrstog materijala u talionik i taljenju šarže čvrstog materijala u talioniku uronjenim izgaranjem, naznačen time što se sastoji u podvrgavanju taline u uzorak tečenja koji pokazuje toroidni uzorak tečenja taline stvoren u talini u talioniku, koji sadrži glavne središnje prema unutra usmjerene konvergentne vektore tečenja na površini taline, gdje je središnja os vrtnje toroida okomica, gdje se uzorak tečenja taline određuje simuliranjem računalnom analizom dinamike fluida.
Per stroke of the slicer, and after cutting to size, a (sellable) veneer is generated having a surface area of approximately 0.6 m2. 
Nakon jednog poteza nožem za rezanje na kriške, i nakon rezanja na potrebnu veličinu, proizvodi se furnir (koji se može prodavati) koji ima veličinu prostora površine od približno 0.6 m".
The bispecific protein of claim 1 or 2, wherein the anti-B7RP1 antibody is a human or humanized IgG2 antibody, or a human or humanized IgG4 antibody. 
Bispecifični protein prema patentnom zahtjevu 1 ili 2, naznačen time što je anti-B7RP1 antitijelo humano ili humanizirano IgG2 antitijelo, ili humano ili humanizirano IgG4 antitijelo.
The method of Claim 5, wherein the composition is in the form of a soil drench liquid formulation. 
Metoda iz patentnog zahtjeva 4, gdje je sastav u obliku tekućine za kvašenje tla.
and X2 independently of one another, represent a nitrogen atom or CR2, with the proviso that at least one of X1 and X2 represents a nitrogen atom; m is 1; and the (CH2)m moiety is optionally substituted by C1-C4alkyl; halogen, carboxy, hydroxy, C1-C4alkoxy, C1-C4-alkylcarbonyloxy, amino, mono- or di-(C1-C4alkyl)amino or acylamino 
X1 1 X2, međusobno neovisno, predstavljaju a atom dušika ili CR2, uz uvjet da najmanje jedan od X1 1 X2 predstavlja atom dušika; m je 1; gdje je ostatak (CH>)m izborno supstituiran s C,-Caalkilom, halogenom, karboksi, hidroksi, C,-Caalkoksi, Ci-Cualkilkarboniloksi, amino, mono- ili di-(C;-Caalkiljamino ili acilamino; nje0,11l12; ili njegova farmaceutski prihvatljiva sol.
A hydro/aero power plant according to claim 2, characterized in that the axles of the rotors of the wind turbines (19) comprise at their ends half-couplings (19a). 
Zračna/hidro elektrana prema zahtjevu 2, naznačena time da osovine rotora vjetroturbina (19) na njihovim krajevima sadrže polu-spojke (19).
wherein heteroaryl is a monocyclic, bicyclic or polycyclic aromatic radical of 5 to 10 ring atoms and containing one or more ring heteroatoms selected from N, O, or S, the remaining ring atoms being C, and when containing two fused rings, the aryl groups may have an unsaturated or partially saturated ring fused with a fully saturated ring. 
pri čemu je aril ciklička, aromatska skupina ugljikovodika s 1 ili 2 aromatska prstena; i pri čemu heteroaril je monociklički, biciklički ili policiklički aromatski radikal s 5 do 10 atoma u prstenu i koji sadrži jedan ili više prstenskih heteroatoma odabranih od N, O ili S, a preostali atomi prstena su C.
• personality changes. 
* - promjene osobnosti.
An installation according to claim 1, wherein damper plates are disposed horizontally in a lower portion of a frame structure of the installation. 
Instalacija prema zahtjevu 1, naznačena time što su prigušne ploče (22) postavljene vodoravno u donjem dijelu konstrukcije okvira (2) instalacije (1).
A dose counter as claimed in any of claims 2 to 3, wherein the actuator mechanism further comprises an actuator shaft mounted for contact by and reciprocating movement with a medicament canister of the metered-dose inhaler, an output portion of the actuator shaft being arranged to engage the input portion of the lever; 
Brojač doze u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je barem jedna osovina pobuđivača (120) i s time povezana poluga (122) gipko otklonjena u odnosu na početnu poziciju, osovina pobuđivača (120) i povezana poluga (122) mogu se pomaknuti prema gipkom otklonu zbog pobuđivanja brojača doze.
is optionally substituted morpholinyl, optionally substituted piperazinyl, or optionally substituted piperidinyl. 
je izborno supstituirani morfolinil, izborno supstituirani piperazinil ili izborno supstituirani piperidinil.
A Form-I crystal of 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide, showing diffraction peaks in its X-ray powder diffraction spectrum at least at the following angles of diffraction 2θ: 9.4 degrees, 9.8 degrees, 17.2 degrees and 19.4 degrees, wherein the X-ray powder diffraction diagram is obtained by using Cu Ka radiation. 
Oblik II kristala 2-{4-[N-(5,6-difenilpirazin-2-il)-N-izopropilamino]butiloksi}-N-(metilsulfonil)acetamida, naznačen time što pokazuje difrakcijske maksimume u svom spektru difrakcije rendgenskih zraka na prahu kod u najmanju ruku sljedećih difrakcijskih kuteva od 2θ: 9,0 stupnjeva, 12,9 stupnjeva, 20,7 stupnjeva i 22,6 stupnjeva, gdje je dijagram difrakcije rendgenskih zraka dobiven uz pomoć zračenja CuKa.
Package according to anyone of claims 1 to 29, characterised in that the package (1; 80; 90; 100) contains tobacco-related articles, wherein the tobacco-related articles are selected from the following group: cigarettes, cigarillos, cigars, tobacco-containing rods, smokeless tobacco, simulated smoking devices, inhalors without combustion of tobacco, aroma reservoirs. 
Omot za pakiranje u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time što omot za pakiranje (1; 80; 90; 100; 110; 130; 150; 180) sadržava proizvode koji su vezani uz duhan, pri čemu su proizvodi koji su vezani uz duhan odabrani iz sljedećih skupina: cigarete, cigarilosi, cigare, šipke koje sadržavaju duhan, duhan bez dima, naprave za simuliranje pušenja, naprave za inhaliranje bez izgaranja duhana, spremnike s aromama.
A method of making a human SAP polypeptide comprising an N-linked oligosaccharide chain, wherein at least one branch of the oligosaccharide chain terminates with a a2,3-linked sialic acid moiety, the method comprising: expressing a human SAP polypeptide in a cell; and 
Postupak za dobivanje humanog SAP polipeptida koji sadržava oligosaharidni lanac vezan na N, pričemu najmanje jedan ogranak oligosaharidnog lanca završava s kiselinskim dijelom sijalične kiseline vezanim na a2,3, naznačen time, da postupak obuhvaća:
wherein the aqueous coating composition comprises water and 0.1 to 5% of a mixture comprising by dry weight: cellulose gum 15-35% 
pri čemu, kompozicija vodenog omotača sadrži vodu i 0.1 do 5% smjese koja sadrži po suhoj težini slijedeće sastojke:
The system according to claim 1, wherein the electric pump is a membrane pump that is selectively activated by a pressure valve after the injection gun is triggered to release liquid from the dosage assembly. 
Sustav prema zahtjevu 1, naznačen time da je električna pumpa membranska pumpa t koja se selektivno aktivira pomoću tlačne sklopke nakon što se pištolj za ubrizgavanje aktivira radi oslobađanja tekućine iz sklopa za doziranje.
A co-suspension according to any preceding claim, wherein the total mass of the suspending particles exceeds the total mass of the active agent particles, at least one of the active agents included in the active agent particles is a highly potent active agent and the ratio of the total mass of the suspending particles to the total mass of the active agent particles is selected from between 10 and 150, between 15 and 125, and between 25 and 75. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što se omjer ukupne mase najmanje jedne vrste suspendirajućih čestice i ukupne mase najmanje jedne vrste čestica sredstva bira između iznad 1 i do 1,5, do 5, do 10, do 15, do 17, do 20, do 30, do 40, do 50, do 60, do 75, do 100, do 150, te do 200.
and R16 are each independently selected from hydrogen, C1-6alkyl or arylC1-6alkyloxycarbonyl; or R15 and R16 together with the nitrogen to which they are attached form morpholinyl or piperazinyl, or piperazinyl substituted with C1-6alkyloxycarbonyl; 
i R16 su svaki nezavisno odabrani od vodika, C1-6alkila ili arilC1-6alkiloksikarbonila; ili i R16 zajedno sa dušikom na koji su spojeni tvore morfolinil ili piperazinil, ili piperazinil supstituiran sa C1-6alkiloksikarbonilom;
Compact fluorescent lamp according to claims 4 or 5 characterized in that cooling apertures (9) are formed on the base (1) and/or on the hollow column (2) and/or on the cap (3). 
Kompaktna fluorescentna žarulja prema zahtjevu 4 ili 5, naznačena time što se otvori za hlađenje (9) nalaze na grlu (1) ifili šupljoj cijevi (2) i/ili poklopcu (3).
A method of manufacturing the crystalline form A of telmisartan (I) characterized in that a carboxylic acid of the general formula R1COOH, wherein R1 is the hydrogen atom or a C1-C4 alkyl, is added to a solution of the potassium salt of telmisartan (VII) in an alcohol of the formula R2OH with the water content lower than 2%, wherein R2 is ethyl or methyl. 
Postupak proizvodnje kristalnog oblika A telmisartana (I) [image] naznačen time, da je karboksilna kiselina opće formule R1COOH, pri čemu je R1 atom vodika ili C1-C4 alkil, dodana u otopinu kalijeve soli telmisartana (VII) [image] u alkohol formule R2OH s vodom čiji je sadržaj manji od 2%, pri čemu je R2 etil ili metil.
to the central portion (30) of at least the second component (6, 62) connected to the first component (4, 60) of each plinth (18), and/or 
sa središnjim dijelom (30) najmanju ruku druge komponente (6, 62), povezanim s prvom komponentom (4, 60) svakog podnožja (18) i/ili
a latch means for holding the spring means in its compressed state after the spring means has been compressed to obtain the brake release position and for releasing the spring means from the compressed state, wherein, upon release of the spring means from the compressed state, the spring means actuates the cam means and moves the face of the at least one of the shoes toward the face of the other of the shoes to obtain the brake applied position, wherein the brake applied position is obtained within a predetermined time from the release. 
uređaj sa zupčastim pogonom (50) koji je spojen na ekscentarska sredstva za komprimiranje elemenata opruge i kojim je moguće upravljati radi kontrole sile koja djeluje na ekscentarska sredstva kada je uređaj uključen između položaja aktivirane kočnice i položaja otpuštene kočnice; te sredstava za zapinjanje za držanje elemenata opruge u njihovom komprimiranom stanju nakon što su elementi opruge komprimirani da se postigne položaj za otpuštanje kočnice i za otpuštanje elemenata opruge iz komprimiranog stanja, naznačen time da nakon otpuštanja elemenata opruge iz komprimiranog stanja, elementi opruge aktiviraju ekscentarska sredstva i pomiču lice barem jedne papučice prema licu druge papučice kako bi se došlo u položaj aktivirane kočnice, pri čemu je položaj aktivirane kočnice postignut unutar prethodno određenog vremena nakon otpuštanja.
The reaction was then cooled to 0 °C. Water was added (3 mL) followed by NaOH (4.29 mmol, 1.43 mL, 3N) and H2O2 (12.88 mmol, 1.32 mL, 30% solution in water). After heating the reaction at 50 °C for 30 minutes, it was cooled to room temperature and quenched by the addition of water. 
Doda se voda (3 mL) i nakon toga NaOH (4.29 mmol, 1.43 mL, 3N) i H2O, (12.88 mmol, 1.32 mL, 30%-tna otopina u vodi).Nakon zagrijavanja reakcijske smjese na 50 * C tijekom 30 minuta, ohladi se na sobnu temperaturu i prekine dodavanjem vode.
A compound represented by the general formula (2): wherein R1 and R2 are each independently a hydrogen atom, a halogen atom, an amino group, a hydroxyl group, a hydroxyamino group, a nitro group, a cyano group, a sulfamoyl group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, a C1 to C6 alkylsulfanyl group, a C1 to C6 alkylsulfinyl group, a C1 to C6 alkylsulfonyl group, or a C1 to C6 alkoxy-C1 to C6 alkylsulfonyl group. 
Spoj prikazan općom formulom (2): [image] naznačen time da su R1 i R2 svaki neovisno vodikov atom, atom halogena, amino skupina, hidroksil skupina, hidroksilamino skupina, nitro skupina, cijano skupina, sulfamoil skupina, C1 do C6 alkil skupina, C1 do C6 alkoksi skupina, C1 do C6 alkilsulfanil skupina, C1 do C6 alkilsulfinil, C1 do C6 alkilsulfonil, ili C1 do C6 alkoksi-C1 do C6alkilsulfonil skupina.
Process according to claim 9, characterized in that the submerged condenser is of the shell and tube type and that the high pressure fluids are on the shell side. 
Postupak sukladno zahtjevu 7, naznačen time što je uronjeni kondenzator tipa sa cjevnim omotačem 1 cjevima i da su tekućine pod visokom tlakom na strani cjevnog omotača.
R1-R2 are independently selected from hydrogen, C1-6-alk(en/yn)yl, C3-8-cycloalk(en)yl, and C3-8-cycloalk(en)yl-C1-6-alk(en/yn)yl; or R1 and R2 together with the nitrogen form a 4-7 membered ring containing zero or one double bond, optionally said ring in addition to said nitrogen comprises one further heteroatom selected from nitrogen, oxygen and sulphur; which ring structure is substituted or unsubstituted as described herein; 
- R'-R" se nezavisno biraju iz vodika, C, g-alk(en/in)il, Cg.g-cikloalk(en)il i C; g-cikloalk(en)il-C, 4-alk(en/injil; ili R' i R" tvore, zajedno s dušikom 4-7-člani prsten koji sadrži nula ili jednu dvostruku svezu a opcicnalno rečeni prsten, uz rečeni dušik, sadrži i jedan heteroatom izabran iz dušika, kisika i sumpora; čija struktura prstena je supstituirana ili ne-supstituirana kako je to ovdje opisano. HR P20080274 T3
The combination as defined in claim 8 wherein the anti-obesity agent is at least one agent selected from the group consisting of rimonabant, orlistat, sibutramine, topiramate, dexamphetamine, phentermine, phenylpropanolamine and mazindol. 
Kombinacija prema patentnom zahtjevu 8, naznačena time što je sredstvo protiv debljine najmanje jedno sredstvo izabrano iz grupe koju čine rimonabant, orlistat, sibutramin, topiramat, deksamfetamin, fentermin, fenilpropanolamin i mazindol.
Additionally, the inventors contemplate a lead composition that includes solid lead having a purity of at least 98%6 (more typically at least 99%, most typically at least 99.5%), molecular hydrogen, and an electroprocessing solvent, wherein the solid lead, the hydrogen, and the electroprocessing solvent form a micro- or nanoporous mixed matrix having a density of less than 5 g/cm3, or of less than 5 g/cm3, or of less than 1 g/cm3. 
Olovna supstanca koja sadrži kruti oblik olova s čistoćom od najmanje 98%, molekularnim vodikom, i ionom olova obogaćeno elektroprocesorsko otapalo koje je vodeno otapalo koje sadrži alkan sulfonsku kiselinu, kelator, i ima pH manji od 7, pri čemu kruti oblik olova, vodik, i elektroprocesorsko otapalo tvori mikroporoznu ili nanoporoznu miješanu matricu gustoće manje od 5 g/em', pri čemu je pH obogaćenog elektroprocesorskog otapala HR P20190579 T1 manji od 7.
A composition as in claim 18 wherein the viscosity of the suspension is greater than 20 cps but less than 500 cps wherein the viscosity of the suspension is measured at a high shear rate of 120 sec-1 at room temperature. 
Pripravak prema patentnom zahtjevu 9, naznačen time, da je viskoznost suspenzije veća od 0,02 Pas (20 cps) ali manja od 0,5 Pas (500 cps), pri čemu se viskoznost suspenzije mjeri pri visokoj brzini smicanja od 120 sec-1 na sobnoj temperaturi.
Beside the effect of colonizing the colon and thereby preventing the proliferation of undesired and harmful bacteria, other health effects of probiotics and possibly also some endogenous beneficial bacteria are: decreasing the incidence or duration of diarrhoea, coping with lactose intolerance, anti-hypertensive effects, decrease in cancer risk, immune system stimulation, etc. 
Osim što naseljavaju debelo crijevo i time sprječavaju proliferaciju neželjenih i štetnih bakterija, među ostale učinke probiotika, a možda i nekih endogenih korisnih bakterija na zdravlje ubrajaju se smanjenje pojavnosti ili trajanja proljeva, ublažavanje nepodnošenja laktoze, antihipertenzijsko djelovanje, smanjenje rizika od raka, stimulacija imunosnog sustava itd.
transfecting or transducing the cells ex vivo with a vector encoding the chimeric receptor; 
transfekcija ili transdukcija stanica ex vivo s vektorom koji kodira dimerni receptor;
Example 27: Preparation of crystalline form I of prasugrel hydrobromide 
Kristalni oblik I prasugrel-hidrobromida u skladu s formulom I: 2 CO-*
The composition according to claim 10, further comprising at least one compound or polypeptide selected from a detectable label or reporter, a TNF antagonist, an anti-infective drug, a cardiovascular (CV) system drug, a central nervous system (CNS) drug, an autonomic nervous system (ANS) drug, a respiratory tract drug, a gastrointestinal (GI) tract drug, a hormonal drug, a drug for fluid or electrolyte balance, a hematologic drug, an antineoplastic, an immunomodulation drug, an ophthalmic, otic or nasal drug, a topical drug, a nutritional drug, a cytokine, and a cytokine antagonist. 
Pripravak koji sadrži najmanje jedno izolirano anti IL-6 protutijelo prema bilo kojem od zahtjeva 1-3 i najmanje jedan farmaceutski prihvatljiv nosač ili otapalo, proizvoljno dalje sadrži najmanje jedan spoj ili polipeptid koji se bira od detektibilnog obilježivača ili reportera, antigonista TNF, protu-infektivnog lijeka, lijeka za kardiovaskularni sustav (CV), lijeka za središnji živčani sustav (CNS), lijeka za autonomni živčani sustav (ANS), lijeka za respiratorni trakt, lijeka za gastrointestinalni trakt (GI), hormonskog lijeka, lijeka za ravnotežu tekućina ili elektrolita, hematološkog lijeka, antineoplastika, imunomodulacijskog lijeka, očni, ušni ili nazalni lijek, topikalni lijek, prehrambeni lijek, citokin, te antagonist citokina.
Process for producing a setting accelerator for a dry mortar blend, the setting accelerator in the form of a powder comprising calcium nitrate, wherein the process comprises the step of spray drying an aqueous solution at least comprising dissolved calcium nitrate, at a temperature between 150°C and 250°C, forming the setting accelerator having a water content between 0,1% and 20, preferably between 0.1% and 5%, and a particle size of 0.1 mm to 1 mm. 
Postupak proizvodnje akceleratora vezivanja za smjesu suhog morta, akcelerator vezivanja je u obliku praška koji sadržava kalcijev nitrat, naznačen time, da postupak obuhvaća korak sušenja raspršivanjem vodene otopine koja sadržava najmanje otopljeni kalcijev nitrat pri temperaturi između 150 *C 1 250 *C, čime se dobiva akcelerator vezivanja koji ima udjel vode između 0,1 % 1 20 %, poželjno između 0,1 % 1 5 %, te veličinu čestica od 0,1 mm do 1 mm.
The use of a compound of the invention as defined herein for the manufacture of a medicament for the prophylaxis or treatment of any of the disease states or conditions described herein. 
Primjena soli prema jednom od zahtjeva 1 do 3 za proizvodnju lijeka za liječenje bolesti, stanja ili poremećaja pobliže opisanim u zahtjevu 10.
The method according to claim 12, wherein reagent (O-reag) is selected from the group consisting of peracetic acid, tort-butylhydroperoxide, oxygen, air, sodium hypochlorite, aqueous H2O2, H2O2 dissolved in acetic acid, H2O2 dissolved in trifluoroacetic acid, and mixtures thereof. 
Postupak prema zahtjevu 12, naznačen time da reagens (O-reag) bude odabran iz skupine koja se sastoji iz peroctene kiseline, terc-butil hidroperoksida, kisika, zraka, natrij hipoklorita, vodene otopine H202, u octenoj kiselini otopljenog H202, u trifluoroctenoj kiselini otopljenog H202 1 njihovih mješavina.
The process according to claim 1, wherein more than 50% of the Li-ion batteries contain 3 wt. % of Co or less. 
Ili 2. gdje veći dio litij-ionskih baterija sadrži maseni udio od 3% kobalta ili manje.
Combined organic extracts are washed with brine and dried over anhydrous sodium sulphate. 
Pomiješane organske ekstrakte ispere se slanom vodom, te HR P20080431 T3 osuši preko bezvodnog natrijevog sulfata.
The microorganism according to any of claims 1 to 6, wherein component (I) and component (II) are linked together to enable the expression and/or secretion of a fusion protein encoded by both components. 
Mikroorganizam u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time, da su sastavni dio (I) i sastavni dio (II) međusobno spojeni kako bi se omogućilo eksprimiranje i/ili izlučivanje fuzijskog proteina koji su kodirali oba sastavna dijela.
The composition according to claim 6 wherein said internal use is an oral, vaginal or rectal use. 
Pripravak u skladu s patentnim zahtjevom 6, naznačen time, da je navedena unutarnja uporaba oralna, vaginalna ili rektalna upotreba.
Such an inseparable connection can be obtained in a variety of ways. 
Takav nerastavljiv spoj može se dobiti na razne načine.
The process according to claim 15, characterized in that the amount of gel expressed by the cellulosic content of the gel in relation to the additional non-fibrillated fibres (dry/dry weight basis) may be about 0.5 to 20 wt%, preferably 1 to 15 wt%, 2 to 10 wt%, 3 to 6 wt%, e.g. 
Postupak prema zahtjevu 15, naznačen time da količina gela izražena kao celulozni udio gela u odnosu na dodatna ne-ftbrilirana vlakna (na bazi težine suhe tvari) može biti oko 0.5 do 20 % tež., poželjno 1 do 15 % tež., 2 do 10 % tež., 3 do 6 % tež., npr.
providing an human SAP polypeptide, and ii) enzymatically or chemically altering the human SAP polypeptide to produce a glycosylated human SAP polypeptide comprising an N-linked oligosaccharide, wherein at least one branch of the oligosaccharide chain terminates with a a2,3-linked sialic acid moiety. 
Glikozilirani humani serumski amiloidni P (SAP) polipeptid za upotrebu u inhibiranju diferencijacije monocita u fibrocite, naznačen time, da SAP polipeptid sadržava N-vezani oligosaharidni lanac i pri čemu barem jedna grana oligosaharidnog lanca završava s a2,3- vezanim ostatkom sijalične kiseline.
It must furthermore be ensured during development of the preparation that no precipitation takes place during the injection. 
Nadalje, za vrijeme razvoja pripravka treba osigurati da neće dolaziti do precipitacije za vrijeme injiciranja.